Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Autophagy pathway regulation in renal tissue refers to the complex network of signaling mechanisms that control the degradation and recycling of intracellular components for cellular quality control and adaptation to stress, particularly in kidney cells. Key regulators include mTOR, AMPK, and FXR, modulating the activity of multiple autophagy-related proteins (ATG proteins, Beclin-1, LC3) in response to injury, metabolic cues, or pharmacological agents. Dysregulation of autophagy plays a vital role in the pathogenesis and progression of kidney diseases including acute kidney injury, chronic kidney disease, and renal fibrosis. However, "autophagy pathway regulation in renal tissue" is not a singular druggable target but a process involving several pathways and molecules.
Induction or inhibition of autophagy via signaling pathways (e.g., mTOR, AMPK, FXR)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autophagy pathway regulation in renal tissue.